Legacy Financial Advisors Inc. Has $1.64 Million Position in Eli Lilly and Company (NYSE:LLY)

Legacy Financial Advisors Inc. raised its stake in Eli Lilly and Company (NYSE:LLY) by 5.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,807 shares of the company’s stock after purchasing an additional 154 shares during the period. Legacy Financial Advisors Inc.’s holdings in Eli Lilly and Company were worth $1,637,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of LLY. Nadler Financial Group Inc. grew its stake in shares of Eli Lilly and Company by 6.8% in the third quarter. Nadler Financial Group Inc. now owns 2,362 shares of the company’s stock valued at $1,269,000 after acquiring an additional 150 shares in the last quarter. Center for Financial Planning Inc. grew its stake in shares of Eli Lilly and Company by 26.5% in the third quarter. Center for Financial Planning Inc. now owns 506 shares of the company’s stock valued at $272,000 after acquiring an additional 106 shares in the last quarter. Stonegate Investment Group LLC grew its stake in shares of Eli Lilly and Company by 0.8% in the third quarter. Stonegate Investment Group LLC now owns 67,681 shares of the company’s stock valued at $36,354,000 after acquiring an additional 537 shares in the last quarter. Affinity Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 1.8% in the third quarter. Affinity Wealth Management LLC now owns 12,916 shares of the company’s stock valued at $6,937,000 after acquiring an additional 228 shares in the last quarter. Finally, Legacy Financial Group LLC acquired a new position in shares of Eli Lilly and Company in the third quarter valued at about $35,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 2.8 %

NYSE LLY traded down $20.94 during trading hours on Friday, reaching $734.97. The company’s stock had a trading volume of 4,595,138 shares, compared to its average volume of 2,629,045. The firm has a fifty day simple moving average of $761.06 and a 200-day simple moving average of $671.38. The stock has a market cap of $698.52 billion, a P/E ratio of 108.24, a P/E/G ratio of 1.46 and a beta of 0.37. Eli Lilly and Company has a 52 week low of $419.80 and a 52 week high of $800.78. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The firm’s quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter last year, the business earned $1.62 EPS. Equities analysts forecast that Eli Lilly and Company will post 13.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. TheStreet upgraded shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Truist Financial increased their price objective on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the stock a “buy” rating in a research note on Wednesday. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $900.00 to $1,001.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective (up from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday, April 30th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus price target of $757.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.